Bifogade filer
PDF
Kurs
-3,95%
Likviditet
0,04 MSEK
Kalender
| Tid* | ||
| 2025-02-18 | 08:00 | Bokslutskommuniké 2024 |
| 2024-11-19 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-20 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-07 | - | X-dag ordinarie utdelning CALMA B 0.00 SEK |
| 2024-06-05 | - | Årsstämma |
| 2024-05-21 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-20 | - | Bokslutskommuniké 2023 |
| 2023-12-14 | - | Extra Bolagsstämma 2023 |
| 2023-11-21 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-22 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-23 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-17 | - | X-dag ordinarie utdelning CALMA B 0.00 SEK |
| 2023-05-16 | - | Årsstämma |
| 2023-02-21 | - | Bokslutskommuniké 2022 |
| 2022-11-22 | - | Kvartalsrapport 2022-Q3 |
| 2022-09-22 | - | Extra Bolagsstämma 2022 |
| 2022-08-23 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-24 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-19 | - | X-dag ordinarie utdelning CALMA B 0.00 SEK |
| 2022-05-17 | - | Årsstämma |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2022-02-23 | - | Bokslutskommuniké 2021 |
| 2021-10-29 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-28 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-19 | - | X-dag ordinarie utdelning CALMA B 0.00 SEK |
| 2021-05-18 | - | Årsstämma |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-12-23 | - | Extra Bolagsstämma 2020 |
| 2020-11-25 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
| 2020-05-15 | - | X-dag ordinarie utdelning CALMA B 0.00 SEK |
| 2020-05-14 | - | Årsstämma |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-25 | - | Kvartalsrapport 2019-Q3 |
| 2019-11-06 | - | Extra Bolagsstämma 2019 |
| 2019-08-27 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-05-10 | - | X-dag ordinarie utdelning CALMA B 0.00 SEK |
| 2019-05-09 | - | Årsstämma |
| 2019-02-28 | - | Bokslutskommuniké 2018 |
| 2018-11-26 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-27 | - | Kvartalsrapport 2018-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Calmark Sweden AB announces today that they are sending 2 units with associated bilirubin test cassettes to the distributor r2 Diagsnostics in India. The distributor plans to use the products for a method comparison.
Calmark, together with r2 Diagnostics, has been working for a long time for a registration of Calmark Neo - Bilirubin on the Indian market. r2 Diagnostics plans to carry out a method comparison at state-accredited laboratories in the country. The result of the method comparison will be submitted to the registration authority in India as a supplement to other submitted material.
"India is an important market for Calmark, even though the registration process is complicated. We hope that this moves the process forward," comments CEO Anna Söderlund.
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se